What is QurAlis?
QurAlis is at the forefront of neurodegenerative research, utilizing proprietary platforms and unique biomarkers to design drugs that directly address disease-causing genetic alterations. Founded by a team of distinguished neurodegenerative biologists from Harvard Medical School and Harvard University, the company is currently advancing a robust pipeline of antisense oligonucleotides and small molecule programs. Their focus on sub-forms of ALS, which account for the majority of patient cases, positions them as a critical player in the precision medicine landscape. The company's methodology emphasizes the translation of complex genetic data into actionable therapeutic interventions, aiming to improve patient outcomes in areas where traditional treatment options have historically failed.
How much funding has QurAlis raised?
QurAlis has raised a total of $150M across 3 funding rounds:
Series A
$42M
Series B
$88M
Debt
$20M
Series A (2020): $42M with participation from Mitsui Global Investment, Dementia Discovery Fund, INKEF Capital, Droia Ventures, MP Healthcare Venture Management, Amgen Business Development, Dolby Family Ventures, Mission BioCapital, Sanford Biosciences, and LS Polaris Innovation Fund
Series B (2023): $88M led by Sanofi Ventures
Debt (2025): $20M, investors not publicly disclosed
Key Investors in QurAlis
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with innovative ideas and transformative technologies of strategic interest.
Mitsui Global Investment
Mitsui & Co. Global Investment, Inc. specializes in guiding innovative entrepreneurs by providing financial support and strategic guidance to help them reach the global stage.
INKEF Capital
INKEF Capital is an Amsterdam-based venture capital firm that focuses on long-term collaboration and active support of innovative technology companies within the healthcare and IT sectors.
What's next for QurAlis?
With the recent influx of capital, QurAlis is well-positioned to scale its clinical development programs and expand its research capabilities. The strategic focus will likely remain on advancing its lead candidates through regulatory milestones while further validating its proprietary platform. As the company transitions into more advanced stages of development, the focus will shift toward operational execution and potential commercialization strategies. The continued support from a diverse syndicate of life science investors underscores the market confidence in the company's ability to deliver breakthrough therapies for patients suffering from debilitating neurodegenerative conditions.
See full QurAlis company page
